Member Info for JSB1989

Slow and steady will do for now. Those shorts were shocking decisions!

The news on LYT-100 can’t be far away now.

I don't understand how EIT can eat up this much stock and not shift the price? EIT were at 3% last summer and have added 11% in the open market. Surely they must be ready to declare their hand?

It was such a risky short to take out. Should be closing but will struggle to given the recent low volumes.

Been trying to break this range and now at the top end. News can’t be far away on either LYT-100 funding or corporate activity.

It’s a fine balance on how much they give up. They could have hit the jackpot if they hadn’t diluted so much in Karuna as they did, however, had it failed at P3, they would have needed to raise off the markets. I’m pleased they aren’t doing the Phase 3 alone as it would become too high risk for me.

It’s a very interesting time for Puretech. There are two likely possible outcomes here IMO. Either they strike a good deal with a big pharma on LYT-100 and continue with the same model as happened with Seaport, Karuna etc or they are bought out by PE or a pharma company.

Theta - Puretech will not be spending huge on the P3. They recognise the cost of this and are seeking support to fund by either spinning out into a new company or have a third party pharma fund or part fund the trials.

The deal for LYT-100 will be done shortly even if they don’t announce it straight away. Once the FDA meeting has concluded, it will be a short turn around to the initiation of the study. I’d expect they are deep into the financing talks now.

It’s ridiculous dallo. But we have said this for years. The shorts have no business to be here. Much easier money to be made elsewhere.

From a TA perspective, the resistance has been broken but it needs to hold above into close.

The change in FVC is huge compared to Boehringer’s drug . This has to flag up with the majors.

Hopefully big pharma will see the value in the data and a good deal can be done. There are a number of options on the table and I’m pleased the company aren’t trying to do it alone.

It’s approaching the end of Q2 so they can’t be far away from announcing how they will move forward with LYT-100 from an ownership perspective.

133-134 is forming into a resistance. Tested three times recently.

First 3 posts looked legitimate and then the holiday stuff turns this into a charade. Professionals are not divulging they are on holiday and drinking beers. If you are in a highly stressful job and need to do some work, you find some time and then shut it down. You don’t give play by plays of what’s on the menu at dinner time.

They dropped a chunk on Friday likely in anticipation of such news.

Dallo - unfortunately pharma has taken a hit by Mr Trump’s comments on the pricing of drugs. Big pharma taken a hit and hasn’t rallied with the rest of the market. That sentiment is likely filtering down across the sector.

I would assume they are having a number of discussions regarding LYT-100 alongside the potential sale of the business to PE.

We won’t see full and fair value here. £2-2.50 will be enough for a buyout. Let’s get it done. For those that have been able to average down will leave with some profit and the end to this frustration.

Thanks for doing this on holiday Justin. It’s a very hard working team and there is clear momentum building.

Over 1000 trades and 5 million+ in volume which indicates some II buying and or short positions closing.

Directors can’t buy in a period where these announcements are made as it can be considered ‘inside trading’.

We need II’s jumping on board.

This is getting silly now. 4 great news updates and this is the best. 300MW and in a new territory! Those who are short need to realise this momentum will only keep building.